Navigation Links
Sinovac Completes Construction of H1N1 Virus Seed Bank
Date:6/15/2009

Production of Seasonal Influenza Vaccine Is Nearly Completed

BEIJING, June 15 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that it has completed construction of the H1N1 virus seed bank necessary to produce a virus antigen.

Sinovac received the seed virus from the US Center for Disease Control (CDC) on June 8, 2009 and started the H1N1 vaccine production on the same day. Sinovac expects to complete production of the first batch and initiate clinical trials of an H1N1 vaccine by the end of July 2009.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "On June 11, 2009, the World Health Organization declared the H1N1 virus a pandemic influenza outbreak. Having completed the construction of our virus seed bank, our H1N1 vaccine production remains on track and we look forward to initiating clinical trials by the end of next month. Sinovac's rapid response to the newly emerged disease outbreak demonstrates the Company's resources and capabilities for vaccine production and highlights our commitment to protect the public from virus transmission through the timely supply of vaccines."

Sinovac's production of Anflu for the 2009/2010 Northern Hemisphere influenza season is nearly completed. The production of H1N1 vaccine will not affect its production and launch of the seasonal flu vaccine for this coming flu season.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine, and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    Helen G. Yang
    Sinovac Biotech Ltd.
    Tel:  +86-10-8289-0088 x9871
    Fax:  +86-10-6296-6910
    Email: info@sinovac.com

    Investors:
    Amy Glynn/Sara Pellegrino
    The Ruth Group
    Tel:  +1-646-536-7023/7002
    Email: aglynn@theruthgroup.com
    spellegrino@theruthgroup.com

    Media
    Janine McCargo
    The Ruth Group
    Tel:  656-536-7033
    Email:  jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Begins the Production of Influenza A (H1N1) Vaccine
2. Chinas Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation
3. Sinovac to Host Conference Call to Report First Quarter 2009 Financial Results
4. Sinovac Biotech Ltd. Files Annual Report on Form 20-F
5. Sinovac Initiates Preparatory Activities for Swine Flu Vaccine
6. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables
7. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
8. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results
9. Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status
10. Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility
11. Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Franz ... Lisp (CL) development tools, and market leader for Semantic Graph Database ... now available within the most effective system for developing and deploying applications to ...
(Date:4/25/2017)... ... ... Leaders of Quorum Review IRB and Kinetiq , the consulting ... Association of Clinical Research Professionals (ACRP) 2017 Meeting & Expo with topics ... excited to present subject matter expertise on topics that impact the global clinical research ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... Webster Bank, today announced first round funding to three startups through the UConn ... financial support to new business startups affiliated with UConn. , The UConn Innovation ...
(Date:4/20/2017)... ... April 20, 2017 , ... As ... webinar will explore challenging patient cases when screening for direct oral anticoagulant. When ... be a need for bridging parental anticoagulation especially for those at high risk ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):